Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $1.84, $0.21 better than the analyst estimate of $1.63. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.38 billion.

GUIDANCE:

Gilead Sciences sees Q4 2018 revenue of $20.8-21.3 billion, versus the consensus of $21.43 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.